PAI-1 expression and its regulation by promoter 4G/5G polymorphism in clear cell renal cell carcinoma

Journal of Clinical Pathology

Volumn 64, Issue 10, 2011, Pages 893-897

  Choi, Jung Woo ^a   Lee, Ju Han ^a   Park, Hong Seok ^a   Kim, Young Sik ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ALLELE; ARTICLE; CANCER GRADING; CLEAR CELL CARCINOMA; CLEAR CELL RENAL CELL CARCINOMA; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DNA POLYMORPHISM; DNA SEQUENCE; FEMALE; GENE EXPRESSION; GENE FREQUENCY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADULT; AGE FACTORS; AGED; CARCINOMA, RENAL CELL; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; FEMALE; GENE FREQUENCY; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; REPUBLIC OF KOREA; RISK ASSESSMENT; RISK FACTORS; SEQUENCE ANALYSIS, DNA; SURVIVAL RATE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 80053192295     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2011-200182     Document Type: Article

References (37)

1. Schmitt M, Janicke F, Moniwa N, et al. Tumor-associated urokinase-type plasminogen activator: biological and clinical significance. Biol Chem Hoppe Seyler 1992;373:611-22.
2. Berger DH. Plasmin/plasminogen system in colorectal cancer. World J Surg 2002;26:767-71. (Pubitemid 36920315)
3. Harbeck N, Kates RE, Gauger K, et al. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer. Thromb Haemost 2004;91:450-6. (Pubitemid 38396866)
4. Nekarda H, Schmitt M, Ulm K, et al. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 1994;54:2900-7. (Pubitemid 24187770)
5. Robert C, Bolon I, Gazzeri S, et al. Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression. Clin Cancer Res 1999;5:2094-102. (Pubitemid 29399264)
6. Bajou K, Masson V, Gerard RD, et al. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol 2001;152:777-84. (Pubitemid 34280162)
7. Czekay RP, Aertgeerts K, Curriden SA, et al. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol 2003;160:781-91. (Pubitemid 36298272)
8. Webb DJ, Thomas KS, Gonias SL. Plasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signaling and thereby promotes MCF-7 cell growth. J Cell Biol 2001;152:741-52.
9. Chen YQ, Sloan-Lancaster J, Berg DT, et al. Differential mechanisms of plasminogen activator inhibitor-1 gene activation by transforming growth factor-beta and tumor necrosis factor-alpha in endothelial cells. Thromb Haemost 2001;86:1563-72. (Pubitemid 34007533)
10. Dong J, Fujii S, Li H, et al. Interleukin-6 and mevastatin regulate plasminogen activator inhibitor-1 through CCAAT/enhancer-binding protein-delta. Arterioscler Thromb Vasc Biol 2005;25:1078-84. (Pubitemid 40627858)
11. Ha H, Oh EY, Lee HB. The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases. Nat Rev Nephrol 2009;5:203-11.
12. Swiatkowska M, Szemraj J, Cierniewski CS. Induction of PAI-1 expression by tumor necrosis factor alpha in endothelial cells is mediated by its responsive element located in the 4G/5G site. FEBS J 2005;272:5821-31. (Pubitemid 41689354)
13. Dawson SJ, Wiman B, Hamsten A, et al. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993;268:10739-45. (Pubitemid 23162248)
14. Grancha S, Estelles A, Tormo G, et al. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease. Thromb Haemost 1999;81:516-21. (Pubitemid 29178933)
15. Burzotta F, Di Castelnuovo A, Amore C, et al. 4G/5G promoter PAI-1 gene polymorphism is associated with plasmatic PAI-1 activity in Italians: a model of gene-environment interaction. Thromb Haemost 1998;79:354-8. (Pubitemid 28065884)
16. Eriksson P, Kallin B, van 't Hooft FM, et al. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 1995;92:1851-5.
17. Chautard D, Dalifard I, Chassevent A, et al. Prognostic value of uPA, PAI-1, and DNA content in adult renal cell carcinoma. Urology 2004;63:1055-60. (Pubitemid 38746802)
18. Hofmann R, Lehmer A, Buresch M, et al. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Cancer 1996;78:487-92. (Pubitemid 26250535)
19. Ohba K, Miyata Y, Kanda S, et al. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis. J Urol 2005;174:461-5. (Pubitemid 40981574)
20. Swiercz R, Wolfe JD, Zaher A, et al. Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype. Clin Cancer Res 1998;4:869-77. (Pubitemid 28183387)
21. Wagner SN, Atkinson MJ, Thanner S, et al. Type-1 plasminogen activator inhibitor in human renal cell carcinoma. J Pathol 1996;179:95-9. (Pubitemid 26182870)
22. Zubac DP, Wentzel-Larsen T, Seidal T, et al. Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy. BMC Urol 2010;10:20.
23. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6:655-63. (Pubitemid 13234762)
24. Edge SB, Byrd DR, Compton CC, et al, eds. AJCC Cancer Staging Manual. Chicago: Springer, 2010:479-89.
25. Falk GFG, Almqvist A, Nordenhem A, et al. Allele specific PCR for detection of a sequence polymorphism in the promoter region of the plasminogen activator inhibitor-1 (PAI-1) gene. Fibrinolysis 1995;9:170-4.
26. Paule B, Deslandes E, Le Mouel SP, et al. Identification of a novel biomarker signature associated with risk for bone metastasis in patients with renal cell carcinoma. Int J Biol Markers 2010;25:112-15.
27. Iwatsuki M, Mimori K, Yokobori T, et al. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci 2010;101:293-9.
28. Kuroda N, Toi M, Hiroi M, et al. Review of sarcomatoid renal cell carcinoma with focus on clinical and pathobiological aspects. Histol Histopathol 2003;18:551-5. (Pubitemid 36362073)
29. Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol 2010;21:212-22.
30. Chong NW, Codd V, Chan D, et al. Circadian clock genes cause activation of the human PAI-1 gene promoter with 4G/5G allelic preference. FEBS Lett 2006;580:4469-72. (Pubitemid 44137351)
31. Dimova EY, Kietzmann T. Cell type-dependent regulation of the hypoxia-responsive plasminogen activator inhibitor-1 gene by upstream stimulatory factor-2. J Biol Chem 2006;281:2999-3005. (Pubitemid 43845767)
32. Ma Z, Jhun B, Jung SY, et al. Binding of upstream stimulatory factor 1 to the E-box regulates the 4G/5G polymorphism-dependent plasminogen activator inhibitor 1 expression in mast cells. J Allergy Clin Immunol 2008;121:1006-12.e2.
33. Smolarz B, Blasiak J, Kulig A, et al. Plasminogen activator inhibitor 1 (PAI-1) levels and gene promoter polymorphisms in subjects with colorectal cancer. J Exp Clin Cancer Res 2001;20:247-52. (Pubitemid 32641068)
34. Sternlicht MD, Dunning AM, Moore DH, et al. Prognostic value of PAI-1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression. Cancer Epidemiol Biomarkers Prev 2006;15:2107-14. (Pubitemid 44877033)
35. Qi L, Allen RR, Lu Q, et al. PAI-1 transcriptional regulation during the G0 ->G1 transition in human epidermal keratinocytes. J Cell Biochem 2006;99:495-507. (Pubitemid 44435566)
36. Zietz B, Drobnik W, Herfarth H, et al. Plasminogen activator inhibitor-1 promoter activity in adipocytes is not influenced by the 4G/5G promoter polymorphism and is regulated by a USF-1/2 binding site immediately preceding the polymorphic region. J Mol Endocrinol 2004;32:155-63. (Pubitemid 38312628)
37. Palmirotta R, Ferroni P, Savonarola A, et al. Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer. Thromb Res 2009;124:403-8.